At a Glance
- Company: Boehringer Ingelheim
- Partner: Immunitas Therapeutics
- Deal value: Up to €407.5 million in milestones, plus royalties
- Focus area: Chronic inflammatory and autoimmune diseases
- Next steps: Advance the antibody towards clinical development
What happened?
Boehringer Ingelheim has licensed a preclinical antibody programme from Immunitas Therapeutics for chronic inflammatory and autoimmune diseases. The deal gives Boehringer worldwide rights to develop, manufacture and commercialise the asset, with payments that could total up to €407.5 million, plus tiered royalties.
Why does it matter?
The asset is designed to go beyond blocking a single inflammatory signal and instead target pathogenic cells that drive chronic inflammation. That could matter for patients who do not respond adequately to current therapies, where deeper and more durable control is still needed.
Who’s behind it?
Boehringer Ingelheim is continuing to build its autoimmune and inflammation pipeline through external deals, and this is its third inflammation-focused business development agreement this year. Immunitas is a Waltham, Massachusetts-based precision immunotherapy company whose single-cell genomics platform helped identify the programme.
How was it achieved?
The agreement covers a preclinical antibody that Immunitas says is designed to selectively target cells central to chronic inflammation, rather than neutralise one cytokine or receptor. Immunitas receives an upfront payment that was not disclosed, while future value depends on development, regulatory and commercial milestones.
What’s next?
Boehringer will push the programme through preclinical work and into clinical development using its global R&D and manufacturing capabilities. If successful, Immunitas stands to receive milestone payments and royalties as the drug advances.